DOXIL for Consolidation Therapy in Ovarian Cancer.

PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

October 31, 2011

Study Completion Date

October 31, 2011

Conditions
Ovarian Neoplasm
Interventions
DRUG

liposomal doxorubicin

Doxil at 50mg/m2 infused over one hour every 3 or 4 weeks for 3-6 cycles

Trial Locations (1)

30342

Southeastern Gynecologic Oncology, Atlanta

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Ortho Biotech, Inc.

INDUSTRY

lead

Southeastern Gynecologic Oncology

OTHER

NCT00248248 - DOXIL for Consolidation Therapy in Ovarian Cancer. | Biotech Hunter | Biotech Hunter